3. McMaster-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy. 2007;27:1029-39.
4. McFarland V et al. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterology. 2009;25(1):24-35.
5. Chopra T, et al. Clostridium difficile Infection in Cancer Patients and Hematopoietic Stem Cell Transplant Recipients. Expert Rev Anti Infect Ther. 2010; 8 (10): 1113-1119.
6. Cornely A, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Diseases. 2012;12(4):281-9.
7. Food and Drug Administration. FDA approves treatment for Clostridium difficile infection [Internet]. [updated May 27 2011; cited September 16 2011]. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc....
8. European Commission. Community register of medicinal products for human use. http://ec.europa.eu/health/documents/community-register/html.... Last accessed January 2012.
9. Pepin J, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-7.
10. Bouza E, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin Micro Infect. 2008;14(Suppl 7):S103-4.
11. Lowy I, et al. Treatment with Monoclonal Antibodies against Clostridium difficile Toxins. N Engl J Med. 2010;362;3:197-205.
12. Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-31.
13. Bauer MP, et al. European Society of Clinical Microbiology and Infectious Disease (ESCMID): treatment guidance document for Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15:1067-79.
14. Ghantoji SS, et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74:309-18
15. Kyne L, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;1;34(3):346-53.
CONTACTO: Abi Dewberry, Ruder Finn, adewberry@ruderfinn.co.uk, Tel:+44(0)20-7438-3051; Mindy Dooa, Astellas Pharma Europe Ltd,mindy.dooa@eu.astellas.com, Tel: +44(0)1784-419-444.
